BioLineRx (BLRX) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Theriva Biologics (TOVX) has outperformed BioLineRx (BLRX) over the past year, losing 49.5% versus a loss of 49.8%. Over five years, BLRX leads with a -98.2% price change compared with -99.8% for TOVX. BioLineRx is the larger company by market cap ($11.3 million vs $10.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | TOVX |
|---|---|---|
| Share price | $2.26 | $0.22 |
| Market cap | $11.25M | $10.10M |
| 1-day change | +1.80% | -3.11% |
| YTD return | -20.22% | +8.14% |
| 1-year return | -49.77% | -49.53% |
| 5-year return | -98.19% | -99.79% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $0.00 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.16 | $0.86 |
| 52-week low | $2.15 | $0.16 |
| Distance from 52-week high | -45.67% | -74.42% |
| Analyst consensus | none | none |
| Avg. price target upside | +873.45% | +1036.36% |
| Average volume | 16.39K | 525.96K |
| Shares outstanding | 4.98M | 45.89M |
| Employees | 20 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
BLRX vs TOVX FAQ
Which is bigger, BioLineRx or Theriva Biologics?
BioLineRx (BLRX) is larger, with a market capitalization of $11.25M compared with $10.10M for Theriva Biologics (TOVX).
Which stock has performed better over the past year, BLRX or TOVX?
TOVX returned -49.53% over the past 12 months, compared with -49.77% for BLRX (price return, excluding dividends). Past performance does not predict future results.
Are BioLineRx and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.